OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Clinical Trials
72
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Conditions
- Significant Bleeding RiskVitamin K-Dependent Coagulation Defect
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 3574
- Registration Number
- NCT06429787
- Locations
- 🇺🇸
Octapharma Research Site, Boston, Massachusetts, United States
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- Conditions
- Acquired Antithrombin Deficiency (Heparin Resistance)
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Octapharma AG
- Target Recruit Count
- 58
- Registration Number
- 2023-507560-39-00
- Locations
- 🇦🇹
Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Medical University of Vienna, AKH, Vienna, Austria
🇷🇴Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu, Bucharest, Romania
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05936580
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇫🇮Helsinki University Hospital,Coagulation Disorder Unit, Helsinki, Finland
🇫🇷Avenue de la République, Chambray-lès-Tours, France
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05935358
- Locations
- 🇮🇳
St. John's Medical College Hospital, Bengaluru, India
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇭🇷University Hospital Centre Zagreb, Zagreb, Croatia
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
Octapharma's PANZYGA Shows Mixed Results in Phase 3 PANS Trial, Achieves Significant Secondary Endpoint
Octapharma's phase 3 trial of PANZYGA for pediatric acute-onset neuropsychiatric syndrome (PANS) missed its primary endpoint of reducing obsessive-compulsive symptoms measured by CY-BOCS score.